Cardiff Oncology Inc (CRDF)

$1.63 +0.07 (4.49%)
Market Cap 105.08M
Revenue (ttm) 680,000.00
Net Income (ttm) -45.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,680.88%
Debt to Equity Ratio 0.00
Volume 406,400
Avg Vol 1,340,336
Day's Range N/A - N/A
Shares Out 67.36M
Stochastic %K 40%
Beta 1.33
Analysts Strong Sell
Price Target $10.25

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
User123321
User123321 Feb. 20 at 1:21 PM
$CRDF It still about the data, not the assumed data. Taking one piece of partially released data may not be the smartest thing to do because it hasn’t been. We shall see. If you waited this long you can wait a little longer. Good luck longs. 😀🙏
1 · Reply
Blakeruss1
Blakeruss1 Feb. 20 at 12:06 PM
$CRDF we are ripping pre market !!!
1 · Reply
BubbaLubsGreen
BubbaLubsGreen Feb. 20 at 11:36 AM
I believe the odds of $CRDF surprising shorts just went in our favor. Carpe diem, longs.
2 · Reply
Lambeerface
Lambeerface Feb. 20 at 5:14 AM
$CRDF This is gonna be alright, baby! It’s gonna be alright, now…
0 · Reply
frogman2000
frogman2000 Feb. 20 at 5:14 AM
$CRDF 72 % ORR for Folfiri regimen across two different trials each with 18 patients. 36 total patients across different trials with 72% ORR Let that sink in on what the FDA is going to say. Not to mention, Oral Non-toxic PFS on first phase 2 trials was 18 months HR on CRDF-004 is .37 putting a PFS over 20 months The market has this wrong and shorts are so screwed
0 · Reply
pharmde
pharmde Feb. 20 at 4:15 AM
$CRDF is our phase 2 our one study?
1 · Reply
suphawk85
suphawk85 Feb. 20 at 4:05 AM
$CRDF FDA drug approvals: Makary and Prasad say one study will be enough | AP News https://share.google/ptOiED95sBwQEhQcf
2 · Reply
Ilikeboating
Ilikeboating Feb. 20 at 2:47 AM
$CRDF Single-Trial Default: The FDA is moving toward requiring only one pivotal clinical trial for new drug approvals, rather than the traditional two, to make the process "more practical"
0 · Reply
Neba_
Neba_ Feb. 20 at 2:29 AM
$CRDF Is the plan to attend the conference next week so that they can skip the earning call without tanking the stock? or what are they going to do on virtual call?😃
0 · Reply
Core366
Core366 Feb. 20 at 1:48 AM
$CRDF Maybe onvansertib is what they really need lol
1 · Reply
Latest News on CRDF
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 7:00 AM EST - 1 day ago

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Jan 28, 2026, 6:23 AM EST - 23 days ago

Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Jan 28, 2026, 2:12 AM EST - 23 days ago

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Jan 27, 2026, 7:05 AM EST - 24 days ago

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

Jan 27, 2026, 7:00 AM EST - 24 days ago

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

CTMX

Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm

Jan 13, 2026, 10:48 AM EST - 5 weeks ago

Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Dec 8, 2025, 4:05 PM EST - 2 months ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Dec 8, 2025, 7:00 AM EST - 2 months ago

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 3 months ago

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 3 months ago

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Nov 4, 2025, 4:01 PM EST - 3 months ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Cardiff Oncology: Preparing For A Defining 2026

Oct 25, 2025, 7:50 AM EDT - 4 months ago

Cardiff Oncology: Preparing For A Defining 2026

Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy

Oct 22, 2025, 7:45 AM EDT - 4 months ago

Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 6 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Jul 30, 2025, 3:27 PM EDT - 7 months ago

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Cardiff Oncology: Data Update Resolves Some Signals

Jul 30, 2025, 11:32 AM EDT - 7 months ago

Cardiff Oncology: Data Update Resolves Some Signals

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jul 29, 2025, 4:07 PM EDT - 7 months ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Jun 27, 2025, 8:30 AM EDT - 8 months ago

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 8 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 17, 2025, 4:05 PM EDT - 8 months ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Jun 2, 2025, 4:05 PM EDT - 9 months ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 14, 2025, 9:05 AM EDT - 10 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 10 months ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

May 2, 2025, 3:35 AM EDT - 10 months ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:10 PM EDT - 11 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Apr 15, 2025, 4:05 PM EDT - 11 months ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:10 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 27, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 20, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Feb 18, 2025, 9:19 AM EST - 1 year ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 12, 2024, 5:38 AM EST - 1 year ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 5:05 PM EST - 1 year ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 7:20 AM EST - 1 year ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Dec 10, 2024, 6:00 AM EST - 1 year ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 4, 2024, 1:10 PM EDT - 1 year ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 12, 2024, 2:57 PM EDT - 1 year ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 8, 2024, 7:37 PM EST - 2 years ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Mar 6, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

User123321
User123321 Feb. 20 at 1:21 PM
$CRDF It still about the data, not the assumed data. Taking one piece of partially released data may not be the smartest thing to do because it hasn’t been. We shall see. If you waited this long you can wait a little longer. Good luck longs. 😀🙏
1 · Reply
Blakeruss1
Blakeruss1 Feb. 20 at 12:06 PM
$CRDF we are ripping pre market !!!
1 · Reply
BubbaLubsGreen
BubbaLubsGreen Feb. 20 at 11:36 AM
I believe the odds of $CRDF surprising shorts just went in our favor. Carpe diem, longs.
2 · Reply
Lambeerface
Lambeerface Feb. 20 at 5:14 AM
$CRDF This is gonna be alright, baby! It’s gonna be alright, now…
0 · Reply
frogman2000
frogman2000 Feb. 20 at 5:14 AM
$CRDF 72 % ORR for Folfiri regimen across two different trials each with 18 patients. 36 total patients across different trials with 72% ORR Let that sink in on what the FDA is going to say. Not to mention, Oral Non-toxic PFS on first phase 2 trials was 18 months HR on CRDF-004 is .37 putting a PFS over 20 months The market has this wrong and shorts are so screwed
0 · Reply
pharmde
pharmde Feb. 20 at 4:15 AM
$CRDF is our phase 2 our one study?
1 · Reply
suphawk85
suphawk85 Feb. 20 at 4:05 AM
$CRDF FDA drug approvals: Makary and Prasad say one study will be enough | AP News https://share.google/ptOiED95sBwQEhQcf
2 · Reply
Ilikeboating
Ilikeboating Feb. 20 at 2:47 AM
$CRDF Single-Trial Default: The FDA is moving toward requiring only one pivotal clinical trial for new drug approvals, rather than the traditional two, to make the process "more practical"
0 · Reply
Neba_
Neba_ Feb. 20 at 2:29 AM
$CRDF Is the plan to attend the conference next week so that they can skip the earning call without tanking the stock? or what are they going to do on virtual call?😃
0 · Reply
Core366
Core366 Feb. 20 at 1:48 AM
$CRDF Maybe onvansertib is what they really need lol
1 · Reply
JN75
JN75 Feb. 20 at 12:04 AM
$CRDF Are things starting to heat up? Wont take much to start a fire.Something smoldering with CRDF.
0 · Reply
BullRun4
BullRun4 Feb. 19 at 10:59 PM
$CRDF Short investors are soon to get burn 🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥 Once the PR is out they have absolutely no time to cover 17-18 days is not enough so short squeeze in play. There is not enough shares out there for them to buy to being with!!!
0 · Reply
cb28
cb28 Feb. 19 at 9:57 PM
$CRDF
1 · Reply
cb28
cb28 Feb. 19 at 9:41 PM
$CRDF wont let me post it all but why did the board sign off on 400k shares at the bottom. Its not typical plus the background of the ceo they know something.
1 · Reply
cb28
cb28 Feb. 19 at 9:37 PM
$CRDF
1 · Reply
cb28
cb28 Feb. 19 at 9:24 PM
$CRDF not sure, ran it through claude seems to insist those meetings along with the bottom price both c suites got rather then the 30d moving avg which is typical is interesting.
1 · Reply
Huber65
Huber65 Feb. 19 at 9:01 PM
$CRDF there is none. Tells me buyout not there yet
0 · Reply
cb28
cb28 Feb. 19 at 8:43 PM
$CRDF looks like there is planned 1v1 meetings. Odd to be confident in these presentations if the ER is also expected to be bad next week.
0 · Reply
Blakeruss1
Blakeruss1 Feb. 19 at 7:12 PM
$CRDF only green stock on Nasdaq today
1 · Reply
lonedaddy
lonedaddy Feb. 19 at 6:58 PM
$CRDF what is the purpose of the oppeheimer conference if they are negotiating a deal. just throwing that out there.
2 · Reply
biohuntress
biohuntress Feb. 19 at 5:47 PM
$CRDF has been on my screen as an MFI divergence last 3 days for what it's worth
1 · Reply
Carmen_27
Carmen_27 Feb. 19 at 5:39 PM
$CRDF Only thing this company has anymore is useless conference appearances and redacted data drops. The housecleaning they did recently looks worse and worse everyday. Likely not because a deal was in the works.
0 · Reply